5-[1-(3,4,5-tribromobenzyl)-1H-1,2,3-triazol-4-yl]nicotinonitrile | 1213234-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-[1-(3,4,5-tribromobenzyl)-1H-1,2,3-triazol-4-yl]nicotinonitrile
• 英文别名: 5-[1-[(3,4,5-tribromophenyl)methyl]triazol-4-yl]pyridine-3-carbonitrile
• CAS: 1213234-98-0
• 化学式: C₁₅H₈Br₃N₅
• 分子量: 497.974
• InChiKey: FRZQZWYPXLOAOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-[1-(3,4,5-tribromobenzyl)-1H-1,2,3-triazol-4-yl]nicotinonitrile 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 C₁₅H₉Br₃N₈
  参考文献：
  名称：

  Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors

  摘要：

  It has been demonstrated that once-a-day dosing of systemically-distributed SCD inhibitors leads to adverse events in eye and skin. Herein, we describe our efforts to convert a novel class of systemically-distributed potent triazole-based uHTS hits into liver-targeted SCD inhibitors as a means to circumvent chronic toxicity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.073
• 作为产物：
  描述：

  5-溴烟腈 在 copper(l) iodide 、 四(三苯基膦)钯 、 copper(ll) sulfate pentahydrate 、 sodium ascorbate 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 5-[1-(3,4,5-tribromobenzyl)-1H-1,2,3-triazol-4-yl]nicotinonitrile
  参考文献：
  名称：

  HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

  摘要：

  结构式I的杂环芳香化合物相对于其他已知的硬脂酰辅酶A去饱和酶(SCD1)，是选择性抑制剂。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；和肝脂肪变性。

  公开号：

  US20110152295A1

文献信息

• [EN] HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] COMPOSES HETEROAROMATIQUES UTILISES EN TANT QU'INHIBITEURS DE LA STEAROYLE-COENZYME A DELTA-9 DESATURASE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2010025553A1

  公开（公告）日：2010-03-11

  Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式I的杂环芳香化合物是选择性抑制硬脂酰辅酶A delta-9去饱和酶（SCD1）相对于其他已知的硬脂酰辅酶A去饱和酶的化合物。本发明的化合物可用于预防和治疗与异常脂质合成和代谢有关的疾病，包括心血管疾病，如动脉硬化; 肥胖症; 糖尿病; 神经系统疾病; 代谢综合症; 胰岛素抵抗和肝脂肪变性。
• Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors
  作者：Jean-Philippe Leclerc、Jean-Pierre Falgueyret、Mélina Girardin、Jocelyne Guay、Sébastien Guiral、Zheng Huang、Chun Sing Li、Renata Oballa、Yeeman K. Ramtohul、Kathryn Skorey、Paul Tawa、Hao Wang、Lei Zhang

  DOI：10.1016/j.bmcl.2011.08.073

  日期：2011.11

  It has been demonstrated that once-a-day dosing of systemically-distributed SCD inhibitors leads to adverse events in eye and skin. Herein, we describe our efforts to convert a novel class of systemically-distributed potent triazole-based uHTS hits into liver-targeted SCD inhibitors as a means to circumvent chronic toxicity. (C) 2011 Elsevier Ltd. All rights reserved.
• HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Leclerc Jean-Philippe

  公开号：US20110152295A1

  公开（公告）日：2011-06-23

  Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式I的杂环芳香化合物相对于其他已知的硬脂酰辅酶A去饱和酶(SCD1)，是选择性抑制剂。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；和肝脂肪变性。